Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease

VOORHEES, N.J., March 1 /PRNewswire/ -- Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC

http://digg.com/u1Oe8z